Pfizer to Invest $120 Million in COVID-19 Pill as Officials Issue Alert

COVID-19 treatment pill Paxlovid in a box at Misericordia hospital in Grosseto, Italy, on Feb. 8, 2022. Jennifer Lorenzini/Reuters

Pfizer announced Monday that it would spend $120 million to expand U.S. manufacturing of its oral COVID-19 antiviral pill at its Michigan facility.

Use of Pfizer’s Paxlovid pill in treatment of newly infected cases has risen even as the U.S. Centers for Disease Control and Prevention (CDC) warned the pill can lead to a rebound in symptoms.